Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Treasury Shares (2022 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Treasury Shares for 4 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Treasury Shares rose 52.58% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, up 52.58% year-over-year, with the annual reading at $1.3 million for FY2025, 52.58% up from the prior year.
  • Treasury Shares hit $1.3 million in Q4 2025 for Protagonist Therapeutics, up from $844708.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.3 million in Q4 2025 to a low of $75500.0 in Q4 2023.
  • Historically, Treasury Shares has averaged $570171.9 across 4 years, with a median of $650612.0 in 2022.
  • Biggest five-year swings in Treasury Shares: crashed 88.84% in 2023 and later soared 1018.82% in 2024.
  • Year by year, Treasury Shares stood at $694414.0 in 2022, then tumbled by 89.13% to $75500.0 in 2023, then skyrocketed by 1018.82% to $844708.0 in 2024, then skyrocketed by 52.58% to $1.3 million in 2025.
  • Business Quant data shows Treasury Shares for PTGX at $1.3 million in Q4 2025, $844708.0 in Q4 2024, and $75500.0 in Q4 2023.